<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu F</submitter><funding>Natural Science Foundation of Hubei Province</funding><funding>Fundamental Research Funds for the Central Universities</funding><funding>National Natural Science Foundation of China</funding><pagination>118</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10170830</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>42(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the most effective temozolomide chemoradiotherapy (RT/TMZ) regimen can only slightly extend survival. How to improve RT/TMZ efficacy remains a major challenge in clinic.&lt;h4>Methods&lt;/h4>Syngeneic G422&lt;sup>TN&lt;/sup>-GBM model mice were subject to RT/TMZ, surgery, piperlongumine (PL), αPD1, glutathione. Metabolomics or transcriptomics data from G422&lt;sup>TN&lt;/sup>-GBM and human GBM were used for gene enrichment analysis and estimation of ROS generation/scavenging balance, oxidative stress damage, inflammation and immune cell infiltration. Overall survival, bioluminescent ima</pubmed_abstract><journal>Journal of experimental &amp; clinical cancer research : CR</journal><pubmed_title>Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8&lt;sup>+&lt;/sup>-T cell immunity.</pubmed_title><pmcid>PMC10170830</pmcid><funding_grant_id>81972362</funding_grant_id><funding_grant_id>2022CFB428</funding_grant_id><funding_grant_id>82173197</funding_grant_id><funding_grant_id>2021GCRC073</funding_grant_id><funding_grant_id>81873854</funding_grant_id><funding_grant_id>81974468</funding_grant_id><pubmed_authors>Zhang TT</pubmed_authors><pubmed_authors>Yin SL</pubmed_authors><pubmed_authors>Zhou Q</pubmed_authors><pubmed_authors>Peng JY</pubmed_authors><pubmed_authors>Jiang HF</pubmed_authors><pubmed_authors>Wu JX</pubmed_authors><pubmed_authors>Chen XQ</pubmed_authors><pubmed_authors>Cao X</pubmed_authors><pubmed_authors>Pan F</pubmed_authors><pubmed_authors>Miao C</pubmed_authors><pubmed_authors>Xu SJ</pubmed_authors><pubmed_authors>He X</pubmed_authors><pubmed_authors>Gao PP</pubmed_authors><pubmed_authors>Liu F</pubmed_authors><pubmed_authors>Xu XH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8&lt;sup>+&lt;/sup>-T cell immunity.</name><description>&lt;h4>Background&lt;/h4>The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the most effective temozolomide chemoradiotherapy (RT/TMZ) regimen can only slightly extend survival. How to improve RT/TMZ efficacy remains a major challenge in clinic.&lt;h4>Methods&lt;/h4>Syngeneic G422&lt;sup>TN&lt;/sup>-GBM model mice were subject to RT/TMZ, surgery, piperlongumine (PL), αPD1, glutathione. Metabolomics or transcriptomics data from G422&lt;sup>TN&lt;/sup>-GBM and human GBM were used for gene enrichment analysis and estimation of ROS generation/scavenging balance, oxidative stress damage, inflammation and immune cell infiltration. Overall survival, bioluminescent ima</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-22T14:42:09.057Z</modification><creation>2025-04-06T01:06:17.496Z</creation></dates><accession>S-EPMC10170830</accession><cross_references><pubmed>37161450</pubmed><doi>10.1186/s13046-023-02686-1</doi></cross_references></HashMap>